Important to keep on hand in case you or a loved one gets covid . . .
https://www.americaoutloud.com/ivermectin-flows-to-americans-via-physician-pharmacist-collaboratives/
In this issue of the McCullough Report, Dr. Denise S. Sibley, from Johnson City, TN, tells our audience how she successfully worked with the legislature of her state through a great deal of effort to ultimately bring into reality, collaborative agreements allowing pharmacists to dispense weight-based dosing courses of oral human ivermectin to ambulatory patients with acute COVID-19.1
In 2022, she provided expert testimony and medical insights to legislators, and she was commended for her exemplary service to the community with a resolution passed by the House and Senate and signed by the Governor.2 These arrangements allow pharmacists to dispense ivermectin to appropriate patients with acute COVID-19 in collaboration with program supervision by a licensed physician who is responsible for that pharmacy.
Now that physicians have had experience with all of the antivirals: hydroxychloroquine, ivermectin, Paxlovid, and mulnipiravir, many doctors have concluded that the most rapidly acting agent is ivermectin and at 0.6 mg/kg per day for 5-10 days, it is the most effective and the safest of all of the drugs in this class of medications.3
While there have been no large (>20,000 patient) clinical trials of ivermectin, the clinical practice experience is now very broad and convincing. Ivermectin has been officially adopted for early treatment in all or part of 22 countries (38 including non-government medical organizations). Combined with several other drugs, most commonly doxycycline, budesonide or prednisone, and aspirin, the medical regimen for the quick-striking Omicron BA.4/5 variants are now streamlined and very easy to administer.
Important to keep on hand in case you or a loved one gets covid . . .
https://www.americaoutloud.com/ivermectin-flows-to-americans-via-physician-pharmacist-collaboratives/
In this issue of the McCullough Report, Dr. Denise S. Sibley, from Johnson City, TN, tells our audience how she successfully worked with the legislature of her state through a great deal of effort to ultimately bring into reality, collaborative agreements allowing pharmacists to dispense weight-based dosing courses of oral human ivermectin to ambulatory patients with acute COVID-19.1
In 2022, she provided expert testimony and medical insights to legislators, and she was commended for her exemplary service to the community with a resolution passed by the House and Senate and signed by the Governor.2 These arrangements allow pharmacists to dispense ivermectin to appropriate patients with acute COVID-19 in collaboration with program supervision by a licensed physician who is responsible for that pharmacy.
Now that physicians have had experience with all of the antivirals: hydroxychloroquine, ivermectin, Paxlovid, and mulnipiravir, many doctors have concluded that the most rapidly acting agent is ivermectin and at 0.6 mg/kg per day for 5-10 days, it is the most effective and the safest of all of the drugs in this class of medications.3
While there have been no large (>20,000 patient) clinical trials of ivermectin, the clinical practice experience is now very broad and convincing. Ivermectin has been officially adopted for early treatment in all or part of 22 countries (38 including non-government medical organizations). Combined with several other drugs, most commonly doxycycline, budesonide or prednisone, and aspirin, the medical regimen for the quick-striking Omicron BA.4/5 variants are now streamlined and very easy to administer.